Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2016 - 2026)
Aurinia Pharmaceuticals (AUPH) reported Current Deferred Revenue of $5.0 million for Q1 2026, up 9.62% on a YoY basis from $4.6 million in Q1 2025, and up 35.38% quarter-over-quarter from $3.7 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals has reported Current Deferred Revenue for 10 years, with the latest figure at $5.0 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 9.62% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 9.62% YoY), and the FY2025 full-year result was $3.7 million, down 66.19% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $5.0 million, up from $3.7 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $11.0 million in Q4 2024, with the low at $3.1 million in Q4 2022.
- Historically, Current Deferred Revenue has averaged $4.8 million across 5 years, with a median of $4.6 million in 2025.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 1556.84% — and 2025, when it sank 66.19%.
- Aurinia Pharmaceuticals' Current Deferred Revenue stood at $3.1 million in 2022, then soared by 52.89% to $4.8 million in 2023, then jumped by 128.59% to $11.0 million in 2024, then slumped by 66.19% to $3.7 million in 2025, then soared by 35.38% to $5.0 million in 2026.
- The last three Current Deferred Revenue figures came in at $5.0 million (Q1 2026), $3.7 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Aurinia Pharmaceuticals | 2.18 Bn | 1.80 Bn | 71.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.04 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 4.59 Mn |
| Dec 31, 2024 | 11.00 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 4.81 Mn |
| Sep 30, 2023 | 4.66 Mn |
| Jun 30, 2023 | 3.23 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 3.15 Mn |
| Dec 31, 2021 | 190,000.00 |
| Dec 31, 2019 | 118,000.00 |
| Dec 31, 2018 | 118,000.00 |
| Dec 31, 2017 | 118,000.00 |
| Dec 31, 2016 | 118,000.00 |